589 completed, 205 unknown, 101 terminated, 86 recruiting. 1111 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 1111 | Completed 589, Unknown 205, Terminated 101, Recruiting 86, Not yet recruiting 56, Withdrawn 51, Active not recruiting 18, Enrolling by invitation 4, Suspended 1 |
Follow Gastrointestinal Diseases: new trials by email Literature Review of Gastrointestinal Diseases trials Research Report on Gastrointestinal Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis High dose budesonide rectal foam, Low dose budesonide rectal foam, Matching placebo rectal foam - Ulcerative Colitis | Phase 4 | Not yet recruiting | Bausch Health Americas, Inc. | 100 | 2029-06-01 | 2026-10-06 |
| ASAPP Study - Topical 5-ASA as Prophylaxis for Pouchitis in Ulcerative Colitis Patients After Pelvic Pouch Surgery 5-ASA, Placebo - Ulcerative Colitis (UC), Pouchitis | Phase 4 | Not yet recruiting | University Hospital, Linkoeping | 110 | 2027-04-01 | 2026-08-19 |
| Povidone-iodine Irrigation for Prevention of Intra-abdominal Abscess in Pediatric Perforated Appendicitis: a Multi-center Stepped Wedge Cluster Randomized Study Irrigation with PVI, Usual care - Acute, Perforated Appendicitis | Phase 4 | Not yet recruiting | The University of Texas Health Science Center, Houston | 1750 | 2027-03-01 | 2025-02-10 |
| Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative Colitis treatment withdrawal - Ulcerative Colitis in Remission | Phase 4 | Not yet recruiting | Assistance Publique Hopitaux De Marseille | 224 | 2027-01-01 | 2026-11-10 |
| MIRICURE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn's Disease Mirikizumab, Fistula Tract Curettage and Closure - Crohn's Disease, Perianal Fistula | Phase 4 | Not yet recruiting | Icahn School of Medicine at Mount Sinai | 50 | 2026-12-01 | 2026-08-24 |
| FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial 1: infliximab 2: filgotinib 3: ustekinumab 4: vedolizumab, 1: ustekinumab 2: vedolizumab 3: infliximab 4: filgotinib, 1: vedolizumab 2: infliximab 3: filgotinib 4: ustekinumab - Ulcerative Colitis (UC) | Phase 4 | Not yet recruiting | University Hospital, Clermont-Ferrand | 240 | 2026-12-01 | 2026-10-21 |
| A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer Zolbetuximab, Oxaliplatin, Folinic Acid - Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Phase 4 | Not yet recruiting | Astellas Pharma Global Development, Inc. | 50 | 2026-11-30 | 2026-09-21 |
| Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose Upadacitinib - Ulcerative Colitis (UC) | Phase 4 | Not yet recruiting | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | 100 | 2026-11-15 | 2026-10-29 |
| Tucatinib Continuation Study tucatinib - HER2-positive Breast Cancer, Cervical Cancer | Phase 4 | Not yet recruiting | Pfizer | 175 | 2026-11-06 | 2026-08-28 |
| A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44) Pembrolizumab, Cisplatin, 5-Fluorouracil - Neoplasm Malignant, Gastric Neoplasms | Phase 4 | Not yet recruiting | Merck Sharp & Dohme LLC | 150 | 2026-11-06 | 2026-09-03 |
| Emerging Indications for Hyperbaric Oxygen Treatment Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis | Phase 4 | Not yet recruiting | Jay C. Buckey Jr. | 100 | 2026-11-01 | 2026-09-09 |
| Vonoprazan High-Dose Dual VS Levofloxacin Concomitant Vonoprazan, Levofloxacin 500mg - Helicobacter Pylori Infection, Peptic Ulcer Disease | Phase 4 | Not yet recruiting | Damascus Hospital | 150 | 2026-11-01 | 2026-06-03 |
| Efficacy of Potassium-Competitive Acid Blockers in Barrett's Esophagus (PCAB BE Study) Potassium-Competitive Acid Blockers (PCABs) - Barrett Esophagus | Phase 4 | Recruiting | University of North Carolina, Chapel Hill | 12 | 2026-11-01 | 2026-11-05 |
| PPI Dosing Per CYP2C19 Genotype CYP2C19 based dosing Proton Pump Inhibitors, Conventional proton pump inhibitor dose - Gastroesophageal Reflux Disease With Esophagitis | Phase 4 | Recruiting | University of Florida | 200 | 2026-11-01 | 2026-11-12 |
| Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity Placebo, Tirzepatide - Obese Adults | Phase 4 | Not yet recruiting | Mayo Clinic | 30 | 2026-10-26 | 2026-10-26 |
| Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis Upadacitinib - UC - Ulcerative Colitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 50 | 2026-10-15 | 2026-09-24 |
| Antibiotics After Incision and Drainage to Prevent Fistula Formation After First Episode of Perianal Abscess Amoxicillin + Clavulanate, Ciprofloxacin + Metronidazole - Perianal Abscess, Anal Fistula | Phase 4 | Not yet recruiting | University of Illinois at Chicago | 236 | 2026-10-05 | 2026-09-21 |
| Risankizumab for Refractory Perianal Fistulizing Crohn's Disease Risankizumab - Crohn Disease, Perianal Fistula | Phase 4 | Recruiting | Yuki Horio | 25 | 2026-10-01 | 2026-10-23 |
| Combination CurQD and Vedolizumab in Ulcerative Colitis CurQD, Placebo, Vedolizumab - Ulcerative Colitis | Phase 4 | Not yet recruiting | Ryan C Ungaro | 160 | 2026-10-01 | 2026-10-05 |
| Assessing the Feasibility of Using Methylene Blue in Identifying Ureters During Colorectal Surgery Intravenous Methylene Blue, Methylene Blue Fluorescence Imaging System - Colorectal Cancer, Colorectal Surgery | Phase 4 | Not yet recruiting | Chinese University of Hong Kong | 20 | 2026-10-01 | 2026-10-06 |
Showing 20 of 1111. Sign in to see all of them.
Crohn Disease (151) · Colitis, Ulcerative (127) · Gastroesophageal Reflux (116) · Colorectal Neoplasms (106) · Inflammatory Bowel Diseases (80) · Stomach Neoplasms (66) · Irritable Bowel Syndrome (58) · Gastrointestinal Hemorrhage (41) · Colonic Neoplasms (38) · Peptic Ulcer (36) · Appendicitis (31) · Esophageal Neoplasms (28) · Esophageal and Gastric Varices (23) · Rectal Neoplasms (22) · Diarrhea (21)
Digestive System Diseases (1104) · Intestinal Diseases (709) · Gastroenteritis (392) · Colonic Diseases (333) · Pathological Conditions, Signs and Symptoms (309) · Neoplasms (266) · Neoplasms by Site (255) · Digestive System Neoplasms (254) · Gastrointestinal Neoplasms (242) · Esophageal Diseases (229) · Inflammatory Bowel Diseases (189) · Pathologic Processes (179) · Rectal Diseases (165) · Intestinal Neoplasms (157)
Esomeprazole (63) · Infliximab (42) · Omeprazole (36) · vedolizumab (32) · Lansoprazole (28) · Rabeprazole (23) · Adalimumab (22) · Metronidazole (22) · Amoxicillin (21) · Pantoprazole (21) · Capecitabine (17) · Mesalamine (17) · Oxaliplatin (17) · Fluorouracil (16) · Sodium Chloride (15)
AstraZeneca (27) · Takeda (22) · Universitaire Ziekenhuizen KU Leuven (16) · Mayo Clinic (15) · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (14) · Xijing Hospital of Digestive Diseases (13) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (8) · Chinese University of Hong Kong (8) · Hoffmann-La Roche (8) · Fudan University (7) · Kaohsiung Veterans General Hospital. (7) · Medical University of Warsaw (7) · University of North Carolina, Chapel Hill (7) · Yonsei University (7) · Asan Medical Center (6)
United States (275) · China (125) · France (59) · South Korea (57) · Canada (54) · Italy (54) · Netherlands (43) · Spain (43) · Denmark (42) · Taiwan (42) · United Kingdom (38) · Belgium (37) · Germany (32) · Israel (27) · Poland (24)
Paula Fernstrom (8) · Arie Levine, MD (5) · Yongquan Shi, Ph. D (4) · Bor-Shyang Sheu, MD (3) · Brian G Feagan, MD (3) · Dan Turner, MD, PhD (3) · Jinming Yu, Ph.D, M.D (3)
PMID 25018650, PMID 40013523, PMID 40357993, PMID 11668104, PMID 23152962, PMID 25478944, PMID 37526194, PMID 10022643, PMID 10049409, PMID 10343249, PMID 10395629, PMID 10403850, PMID 10536559, PMID 10626860, PMID 10896917, PMID 10950834, PMID 11052511, PMID 11156645, PMID 11256129, PMID 11822956, PMID 11857360, PMID 12041718, PMID 12127688, PMID 12161727, PMID 12170403, PMID 12194122, PMID 12219064, PMID 12432298, PMID 12492746, PMID 1305308, PMID 14570648, PMID 14644354, PMID 14762782, PMID 1479177, PMID 1499440, PMID 15044883, PMID 15058524, PMID 15094271, PMID 15168373, PMID 15479678, PMID 15488052, PMID 15519198, PMID 15555725, PMID 15572881, PMID 15645403, PMID 15738894, PMID 15793647, PMID 15818423, PMID 15838899, PMID 15843939
2014 (12), 2025 (8), 2015 (6), 2009 (5), 2017 (5), 2016 (4), 2019 (4), 2008 (3), 2018 (2), 2023 (2), 2005 (1), K12TR004908 (1), K23DK115827 (1), K23DK124567 (1), K23DK131317 (1)